Fludarabine

別名：FaraA, Fludarabinum, NSC 118218

製品コード：S1491 純度：99.96%

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.

CAS No. 21679-14-1

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
10mg	JPY 22000	国内在庫あり
50mg	JPY 55500	国内在庫あり
200mg	JPY 103500	国内在庫あり
1g	JPY 220500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（191）

製品安全説明書

現在のバッチを見る：純度： 99.96%

99.96

Fludarabine関連製品

関連ターゲット	STAT1 STAT3 STAT5 STAT6	もっと見る
関連製品	Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) SH-4-54 C188-9 BP-1-102 Napabucasin (BBI608) HO-3867 Nifuroxazide AS1517499 Homoharringtonine (HHT) STAT5-IN-1 Ochromycinone (STA-21) HJC0152 APTSTAT3-9R STAT3-IN-1 SC-1 Narciclasine SH5-07 (SH-5-07) Scutellarin	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Tyrosine Kinase Inhibitor Library JAK/STAT compound library	もっと見る

シグナル伝達経路

STATシグナル伝達経路

STAT阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
EHEB	Apoptosis Assay	40 μM	24 h	induces apoptosis	23497075
HEC50B	Apoptosis Assay	20/100 μM	24 h	induces apoptosis slightly	23595697
AN3CA	Apoptosis Assay	20/100 μM	24 h	induces apoptosis in a dose-dependent manner	23595697
HEC1A	Apoptosis Assay	20/100 μM	24 h	induces apoptosis in a dose-dependent manner	23595697
HEC50B	Growth Inhibition Assay	100-500 μM	24 h	inhibits cell growth slightly	23595697
AN3CA	Growth Inhibition Assay	100-500 μM	24 h	inhibits cell growth in a dose-dependent manner	23595697
HEC1A	Growth Inhibition Assay	100-500 μM	24 h	inhibits cell growth in a dose-dependent manner	23595697
Reh	Function Assay	10 μM	1/2/4 h	induces autophagy	23681223
Nalm-6	Function Assay	10 μM	1/2/4 h	induces autophagy	23681223
DU-145	Growth Inhibition Assay	0-10 μg/ml	48 h	inhibits cell growth in a dose-dependent manner	23734815
NALM6	Apoptosis Assay	5 μM	24 h	induces cell apoptosis	24057147
I-83	Apoptosis Assay	5 μM	24 h	induces cell apoptosis	24057147
BJAB	Apoptosis Assay	5 μM	24 h	induces cell apoptosis	24057147
HMECs	Function Assay	100 μM	36 h	inhibits IFNα mediated phosphorylation of STAT1 and STAT3, but not of STAT2	24211327
HMECs	Function Assay	100 μM	36 h	inhibits IFNγ and LPS induced STAT1 phosphorylation and IRF1 expression	24211327
624.38mel	Function Assay	50-200 μM	24 h	inhibits IDO activity independently of mRNA levels	24911872
MDA-231	Function Assay	50-200 μM	24 h	inhibits IDO activity independently of mRNA levels	24911872
624.38mel	Function Assay	50 μM	24 h	decreases IDO expression	24911872
MDA-231	Function Assay	100 μM	24 h	decreases IDO expression	24911872
PBMC	Function Assay	50/100 μM	24 h	inhibits STAT1 phosphorylation	24911872
Raji	Function Assay	3 μM	24/48/72 h	induces accumulations of p53, p63 and p73	24940695
KBM3/Bu2506	Apoptosis Assay	2.5 μM	48 h	induces apoptosis slightly	25111583
MOLM 13	Apoptosis Assay	2.5 μM	48 h	induces apoptosis slightly	25111583
THP-1	Apoptosis Assay	2.5 μM	48 h	induces apoptosis slightly	25111583
MV-4-11	Apoptosis Assay	2.5 μM	48 h	induces apoptosis slightly	25111583
Jeko-1	Function Assay	20 μM	24 h	inhibits expression of IDO	25940712
CLL	Apoptosis Assay	10 μM	24-96 h	induces apoptotic cell death	22207686
MEC1	Apoptosis Assay	100 μM	72 h	induces apoptosis significantly	22132973
U937	Apoptosis Assay	0.8 μM	4-48 h	induces apoptosis slightly	22074700
U937	Apoptosis Assay	1 μM	96 h	induces apoptosis slightly	22023523
Daudi	Apoptosis Assay	20 μM	96 h	induces apoptosis slightly	22023523
J45.01	Apoptosis Assay	1 μM	96 h	induces apoptosis slightly	22023523
NALM-6	Apoptosis Assay	10 μM	24 h	induces cell apoptosis slightly	21699383
JMV-3	Apoptosis Assay	10 μM	24 h	induces cell apoptosis slightly	21699383
EHEB	Function Assay	5-50 μM	24 h	decreases p21 expression significantly	21168391
JVM-2	Function Assay	30 μM	24 h	decreases p21 expression	21168391
KBM3/Bu2506	Growth Inhibition Assay	0.6 μM	24 h	increases the cell fraction in S-phase	20933509
HLE-B3	Function Assay	25 μM	48 h	blocks IFN-γ–induced STAT1 phosphorylation and IDO expression	20435158
SKW6.4	Apoptosis Assay	0.01-10 μM	24/48 h	induces cell death in both time- and dose- dependent manner	18092340
CCRF-CEM	Function assay	10 uM	1 to 60 mins	Drug transport in human CCRF-CEM cells assessed as ENT1-mediated uptake at 10 uM after 1 to 60 mins by liquid scintillation counting analysis	23388705
K562	Growth Inhibition Assay		72 h	IC50=3.3 nM	20307198
RPMI 8226	Growth Inhibition Assay		24 h	IC50=1.54 μM	17976186
MM.1S	Growth Inhibition Assay		48 h	IC50=13.48 μM	17976186
MM.1R	Growth Inhibition Assay		48 h	IC50=33.79 μM	17976186
CLL5	Antitumor assay		48 hrs	Antitumor activity against CLL5 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.16 μM.	24673739
K562	Cytotoxicity assay		72 hrs	Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay, IC50 = 0.26 μM.	20605656
CLL3	Antitumor assay		48 hrs	Antitumor activity against CLL3 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.35 μM.	24673739
CLL4	Antitumor assay		48 hrs	Antitumor activity against CLL4 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 0.64 μM.	24673739
CEM-DNR-B	Cytotoxicity assay		72 hrs	Cytotoxicity against human CEM-DNR-B cells after 72 hrs by MTT assay, IC50 = 1.01 μM.	20605656
CLL6	Antitumor assay		48 hrs	Antitumor activity against CLL6 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 1.6 μM.	24673739
CLL2	Antitumor assay		48 hrs	Antitumor activity against CLL2 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 2.66 μM.	24673739
HCT116	Cytotoxicity assay		72 hrs	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay, IC50 = 6.6 μM.	25462277
PBMC	Cytotoxicity assay		48 hrs	Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells, IC50 = 10 μM.	25562417
CLL1	Antitumor assay		48 hrs	Antitumor activity against CLL1 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis, EC50 = 17.1 μM.	24673739
CEM	Cytotoxicity assay		72 hrs	Cytotoxicity against human CEM cells after 72 hrs by MTT assay, IC50 = 19.49 μM.	20605656
T47D	Cytotoxicity assay		72 hrs	Cytotoxicity against human T47D cells after 72 hrs by SRB assay, IC50 = 46.2 μM.	25462277
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 47.44 μM.	20605656
Reh	Growth Inhibition Assay			IC50 ∼10 μM	23681223
Nalm-6	Growth Inhibition Assay			IC50 ∼10 μM	23681223
Nalm-6-FluR	Growth Inhibition Assay			IC50=250 μM	25061101
Molt-4	Growth Inhibition Assay			IC50=180 μM	25061101
RPMI-8226	Growth Inhibition Assay			IC50=500 μM	25061101
Mec-1	Growth Inhibition Assay			IC50＞500 μM	25061101
U2937	Growth Inhibition Assay			IC50=16 μM	25061101
Reh	Growth Inhibition Assay			IC50=30 μM	25061101
Nalm-6	Growth Inhibition Assay			IC50=18 μM	25061101
A549	Growth Inhibition Assay			IC50=15.7±2.8 µM	23377192
A549 GAPDH-deficient	Growth Inhibition Assay			IC50=18.5±2.3 µM	23377192
RPMI 8226	Growth Inhibition Assay			IC50=25.9 ± 3.7 μM	21948264
CEM	Growth Inhibition Assay			IC50=2.4 ± 0.4 μM	21948264
Raji	Growth Inhibition Assay			IC50=0.47 ± 0.04 μM	21948264
U937	Growth Inhibition Assay			IC50=0.24 ± 0.04 μM	21948264
K562	Growth Inhibition Assay			IC50=0.44 ± 0.05 μM	21948264
KBM3/Bu2506	Growth Inhibition Assay			IC20=0.67 µM	20933509
MDA-MB-231	Growth Inhibition Assay			IC50=4.0 μM	20447390
MCF-7	Growth Inhibition Assay			IC50=15.0 μM	20447390
BW-225	Growth Inhibition Assay			IC20=1.37 ×10−8 μM	18661380
OH-65	Growth Inhibition Assay			IC20=1.37 ×10−8 μM	18661380
GR-145	Growth Inhibition Assay			IC20=2.74 × 10−8 μM	18661380
A549	Growth Inhibition Assay			IC20=5.48 × 10−8 μM	18661380
CaSki	Growth Inhibition Assay			IC20=1.37 × 10−7 μM	18661380
ZMK-1	Growth Inhibition Assay			IC20=1.37 × 10−6 μM	18661380
U937	Growth Inhibition Assay			IC50=3,200 ± 560 nM	15930361
primary CLL	Cytotoxicity assay			Cytotoxicity against human primary CLL cells, LD50 = 1.1 μM.	25148392
CHO	Function assay			Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat adenosine A3 receptor, Ki = 10.4 μM.	7707320
JVM2	Antitumor assay			Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis, EC50 = 10.4 μM.	24673739
HeLa	Antitumor assay			Antitumor activity against human HeLa cells assessed as cell viability by MTT assay, EC50 = 16 μM.	24673739
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
U-2 OS	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	29435139
U-2 OS	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
Daoy	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

STAT1 ^[5]
(Vascular smooth muscle cells)

In Vitro
In vitro	Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. ^[1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. ^[2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. ^[3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. ^[4] Fludarabine is an inhibitor of STAT1 that specifically reduces STAT1 without affecting other STAT family members^[5]. In addition to cytoplasmic accumulation, repeated low-dose cisplatin (RLDC) induces HMGB1 expression, which is marked suppressed by STAT1 knockdown. Consistently, fludarabine suppresses HMGB1 expression during RLDC treatment dose-dependently in RLDC-treat renal tubular cells^[5].
細胞実験	細胞株	Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
	濃度	2 μg/mL
	反応時間	24 hours
	実験の流れ	After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 10⁵ cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	procaspase-9 / procaspase-3 p-p53 / p53 STAT1		27223263
	Immunofluorescence	α-SMA / Vimentin		28322315
	Growth inhibition assay	Cell viability		24956101

In Vivo
In Vivo	Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. ^[1]
動物実験	動物モデル	Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
	投与量	40 mg/kg
	投与経路	Administered via i.p.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05390814	Recruiting	Primary Central Nervous System Lymphoma	Assistance Publique - Hôpitaux de Paris	December 18 2023	Phase 1
NCT05201183	Withdrawn	Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Lymphocytic Leukemia\|Myelodysplastic Syndromes	Naoyuki G. Saito M.D. Ph.D.\|Indiana University	October 2023	Phase 1\|Phase 2
NCT05917405	Recruiting	Acute Myeloid Leukemia in Remission	Nantes University Hospital	September 14 2023	Phase 2

参考
[1] Meng H, et al. Eur J Haematol. 2007, 79(6), 486-493. [2] Brachwitz H, et al. Bioorg Med Chem. 1999, 7(6), 1195-1200. [3] Fernández-Calotti P, et al. Int Immunopharmacol. 2006, 6(5), 715-72 [4] Zaffaroni N, et al. Eur J Cancer. 1996, 32A(10), 1766-1773. [5] Fu Y, et al. Theranostics. 2023 May 8;13(9):2757-2773. + 展開

参考

+ 展開

化学情報

分子量	285.23	化学式	C₁₀H₁₂FN₅O₄
CAS No.	21679-14-1	SDF	Download Fludarabine SDFをダウンロードする
Smiles	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 57 mg/mL ( (199.83 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

よくある質問（FAQ）

質問1:
how to re-suspend and deliver the inhibitor for in vivo experiments?

回答
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):